Specimen (redacted) Serotype 4Serotype 6BSerotype 9VSerotype 14 3 Serotype 19F Target ELISA Values 1 Median Luminex Values 2 Target ELISA Values 1 Median.

Slides:



Advertisements
Similar presentations
HIV Counselling and Testing
Advertisements

To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Clinical Microbiology and Immunology 1 36 Copyright © McGraw-Hill Global Education Holdings, LLC. Permission required for reproduction or display.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
Vaccines and Related Biological Products Advisory Committee Meeting
Gestational diabetes mellitus (GDM), a common medical complication of pregnancy, is defined as “any degree of glucose intolerance with onset or first.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
EOH:2504 Principles of Environmental Exposure Instructor: Dr. Volz Yi-Han Huang EOH MPH student Dec
Research Techniques Made Simple: The Use of Luminex Assays To Measure Cytokines Saami Khalifian, B.A., Giorgio Raimondi, Ph.D., & Gerald Brandacher, M.D.
Diagnostic Microbiology and Immunology
1 URINALYSIS AND BODY FLUIDS (AMNIOTIC FLUID) LECTURE Dr. Essam H. Jiffri.
Introduction to Immunoassays
Microbiology B.E Pruitt & Jane J. Stein AN INTRODUCTION TORTORA FUNKE CASE Chapter 18 Practical Applications of Immunology.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
OnSite Rubella IgG/IgM Rapid Test Novel Unique & Only Semi-Quantitative 4-Line Rapid Test.
Vaccines and Related Biological Products Advisory Committee Meeting
CBER Perspective VRBPAC Meeting, November 16, 2010.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Neonatal Group B Streptococcal Infections
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
Splenectomy Vaccine Protocol PIDPIC Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Simoa Accelerator Laboratory
Applications of Immune Responses
Healthy Kansans living in safe and sustainable environments.
Multiple Choice Questions for discussion
A double-blinded, controlled study of the efficacy, immunogenicity, safety and tolerability, and effectiveness of a pneumococcal conjugate vaccine containing.
Viral Hepatitis - Historical Perspective A “Infectious” “Serum” Viral hepatitis Entericallytransmitted Parenterallytransmitted F, G, ? other E NANB BD.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Use of Immunogenicity Data to Assess Vaccine Effectiveness Cara R. Fiore, Ph D Microbiologist, Master Reviewer Office of Vaccines Research and Review Center.
Copyright © 2009 Pearson Education Inc., publishing as Pearson Benjamin Cummings Chapter 17: Immunization and Immune Testing.
Copyright © 2009 Pearson Education Inc., publishing as Pearson Benjamin Cummings Chapter 17: Immunization and Immune Testing.
Serum procalcitonin and C-reactive protein in children with community- acquired pneumonia K.Gogvadze, I.Guramishvili, I.Chkhaidze, K.Nemsadze, T.Maglakelidze.
Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.
Quality Assurance for Pneumococcal Assays in Europe Daniel Harrison.
Applications of Immune Responses Chapter 17. Principles of Immunization Naturally acquired immunity is acquisition of adaptive immunity through natural.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
SMFM Clinical Practice Guidelines Tdap Vaccination in pregnancy Society of Maternal Fetal Medicine with the assistance of Neil Silverman, MD Published.
Effectiveness of Sub-capsular Meningococcal Vaccines An Approach to Evaluate Vaccines for the Prevention of Invasive Group B Meningococcal Disease VRBPAC.
Functional antibody activity as measured by opsonophagocytosis Sandra Romero-Steiner, Ph.D. Respiratory Diseases Immunology Laboratory.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
Author: Cheng-Chi Wang, Chi-Huey Wong
N Engl J Med 2010; 362: January 28, 2010 Presenters ; Dr Ngwenya/Dr Nchimba.
Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
BioPlex 2200 HIV Ag-Ab Assay
Vaccination Info. Journal of immunology Vaccination of HCWs was associated with reductions in total patient mortality from 17% to 10% (odds ratio [OR],
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
Active immunity and vaccination What is immunisation? The process by which a person develops immunity to a disease causing organism. i.e. the blood contains.
 Direct  Indirect  Direct: -Microscopy -Culture -Antigen -Nucleic acid  Indirect: -Specific antibody (Serology)
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory.
The ELISA Enzyme-Linked ImmunoSorbent Assay A highly specific and sensitive procedure allowing evaluation of multiple agents for a single serum dilution.
15283 New Sensitive and Specific Rapid HSV-2 Antibody Test Objective To describe the performance and uses of a new HSV-2 specific serological rapid test,
Guidelines for Vaccinating Dialysis Patients BY: DR. JONAIDI ASSOCIATE PROF. OF INFECTIOUS DISEASES.
EPIDEMIOLOGY OF INFNT DENGUE CASES ILLUMINATES SEROTYPE- SPECIFICITY IN THE INTERACTION BETWEEN IMMUNITY AND DISEASE AND CHANGES IN TRANSMISSION DYNAMICS.
Multiplex analysis of cytokines Russell Garland KWS BioTest
* LABORATORY-BASED SURVEILLANCE OF S. PNEUMONIAE INVASIVE DISEASE (IPD) IN CHILDREN: SEROTYPE DISTRIBUTION AND ESTIMATION OF VACCINES COVERAGE B. V. M.
Vaccine Efficacy, Effectiveness and Impact
Specific Immunity and Immunization
ImmunoWELL Zika Virus Serology.
Facilitator: Pawin Puapornpong
Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms  Toby J. Williams, Catherine A. Jones,
Overview of Pertussis Diagnostics
Presentation transcript:

 Specimen (redacted) Serotype 4Serotype 6BSerotype 9VSerotype 14 3 Serotype 19F Target ELISA Values 1 Median Luminex Values 2 Target ELISA Values 1 Median Luminex Values 2 Target ELISA Values 1 Media n Lumin ex Values 2 Target ELISA Values 1 Media n Lumin ex Values 2 Target ELISA Values 1 Media n Lumin ex Values A 5 Serotype Comparison between the Luminex and ELISA Methods for Estimating Pneumococcal IgG Antibody Concentration D.L. Klein; 1 M. H. Hickey; 1 M. Steinhoff; 2 1 Flow Applications, Inc., Atlanta, GA; 2 Johns Hopkins School of Public Health, Baltimore, MD ABSTRACT TITLE: Correlation between Luminex and ELISA methods for estimating pneumococcal IgG antibody concentration BACKGROUND: The standard measurement of pneumococcal (Pn) antibody is by ELISA. The assay has several limitations that result in substantial laboratory efforts at a relatively high cost. We compared the standard ELISA with a new multiplex anti-Pn IgG Luminex-based assay that relies on the conjugation of Pn polysaccharide to an array of color-coded microspheres and a flow cytometric detection system. In situations where only small quantities of blood or large numbers of samples are involved, and immunoassay that measures multiple IgG specificities to multiple antigens simultaneously from a single sample is highly advantageous. METHODS: Using pre- and post-vaccination sera collected from 100 pregnant Bangladesh subjects immunized during their third trimester with a 23-valent Pn polysaccharide vaccine, we compared the ELISA data with the Luminex-based multiplex assay using a WHO calibrated Pn reference serum. All sera were assessed for anti-Pn IgG specific for Pn serotypes 4, 6B, 9V, 14, and 19F. We have evaluated the statistical correlation between the ELISA and multiplex data for each serotype. PRELIMINARY DATA: 11 serum specimens were evaluated in both assays, and the titers compared with a Mann Whitney test and regression analysis. For the serotypes 4, 9V, 14, and 19F, the median titers were statistically similar (p=0.7 to 0.5), and the correlation coefficients ranged from 0.84 to 0.99, with >90% of the values meeting the criterion of +/- 40% of the consensus value. The multiplex assay was also very reproducible and robust with coefficients of variation under 10% and in some cases under 2%. DISCUSSION: These data suggest that the Luminex-based multiplex assay has a high degree of correlation with the standard traditional ELISA. The use of the multiplex assay should reduce the cost and time to obtain Pn antibody data and help promote the licensure of future Pn vaccines and other encapsulated bacterial pathogens. BACKGROUND It has been proposed by the World Health Organization (WHO) that vaccination of the mother and transfer of maternal antibody across the placenta to the newborn infant should provide protection against pneumococcal (Pn) infection. This approach is the current strategy for prevention of neonatal and newborn tetanus in developing countries. Based on previous studies, use of the 23-valent polysaccharide (Ps) vaccine during pregnancy is safe and results in maternal transfer of high levels of specific IgG antibody to the newborn and protects them from Streptococcus pneumoniae in early infancy. Thus, a strong case can be made for the use of maternal vaccination as a mechanism for preventing serious illness or death in both young infants and pregnant women. To control high morbidity and mortality rates in newborns due to Pn disease, 340 healthy pregnant women in Bangladesh were vaccinated with a 23-valent Pn vaccine during their third trimester as part of a randomized, double-blinded trial. The effect of maternal vaccination on anti-Pn IgG to capsular Ps was measured by both the traditional enzyme-linked immunosorbent assay (ELISA) and a modified multiplexed anti-Pn IgG Luminex-based quantitation assay (LEXA) that relies on novel chemistry for conjugating PnPs to an array of color-coded microspheres and a flow cytometric detection system. The latter assay was developed by Flow Applications, Inc. to avoid many of the limitations associated with the traditional antibody measurement of ELISA. A set of 12 WHO reference sera and clinical samples from the above trial was used to demonstrate accuracy and precision of the LEXA. Quantitative IgG Luminex Assay A human, bead-based, multiplex Luminex quantitative assay or LEXA was optimized and validated for the measurement of antibodies to PnPs in large numbers of patient sera associated with vaccine clinical trials and epidemiology studies. The assay relies on a rapid particle-based flow cytometric system that allows a single sample to be tested simultaneously for a number of different biomolecules/analytes. The Luminex 100 platform was used to acquire data from a multiplexed assay using a capture bead system developed by the Luminex Corporation (Fig. 1). Purified capsular PnPs were obtained from the ATCC. The labeled beads serve as a solid support for the antigen and permit the simultaneous analysis of antibodies with specificities for up to 100 different antigens in a single reaction and a high through-put screening of up to 1000 sera per day. The bead-serum reaction mixture was then read in a dual laser (two-color analysis) flow cytometer. Prior to use in the assay, sera were adsorbed with cell wall Ps and type 22 Ps to improve specificity by removing antibody to cell wall Ps, cross-reacting epitopes, and contaminating cell wall protein. This procedure was compared to the WHO standard ELISA to establish correlation values for each of 5 different Pn serotypes. DESIGN Population: A prospective, randomized, double-blinded, control trial was evaluated in 4 groups of mothers and their infants (Fig. 2). During the trial, a 23-valent PnPs vaccine or a licensed inactivated influenza vaccine was administered to 340 healthy women in Bangladesh 18 to 40 years of age who were in their third trimester of gestation. Mothers were recruited in private practices after signing consent forms. Primary outcome measures: 1) evaluate immunogenicity and safety characteristics of a conjugate Pn vaccine administered to infants of mothers who had been immunized with PnPs vaccine during their third trimester of pregnancy; 2) evaluate the effect of high levels of maternal antibody on the infant’s response to 3 doses of the Pn conjugate vaccine given in the routine infant schedule; 3) continue surveillance of infants from 6 months to 15 months of age and assess for illness and nasopharyngeal carriage; 4) determine duration of mothers’ Pn antibody response; and 5) determine whether immune infants following maternal immunization demonstrate an enhanced antibody response to exposure to PnPs at 12 months of age. Design Summary: Blood specimens were collected in the mothers before and after immunization and at the time of birth. For infants, cord blood, along with venous and nasal swab specimens, was collected at various times followed by a single dose of PnPs vaccine at 12 months and a subsequent dose of either Hib conjugate or Pn conjugate vaccine (Table 1). With regard to intervention, mothers received a single immunization during their third trimester of pregnancy while infants, born to these mothers, received the normal 3 doses of licensed Pn conjugate or Haemophilus influenzae type b (Hib) conjugate vaccine as well as all the other routine vaccines administered in childhood. Discussion The LEXA has a greater dynamic range than the ELISA and, thus, significantly reduces the need for multiple dilutions of each serum sample in addition to increasing the accuracy and reproducibility of the assay. The LEXA showed a positive correlation with a conventional ELISA procedure for serotypes 4, 6B, 9V, 14, and 19F in mothers’ sera. In addition, both the LEXA and ELISA demonstrated strong post-vaccine responses in mothers’ sera that were in general agreement. On a routine basis, the incubation times and total assay times of the LEXA were much less than ELISA. The simultaneous quantitation of different antigens in a single sample from vaccinated or naturally infected subjects using the LEXA means that greatly reduced sample sizes are needed as well as greatly reduced amounts of time, labor, and reagent costs when measuring immunological activity of sera. Results from the LEXA suggest that it has a greater sensitivity and specificity than that of the standard ELISA. The LEXA provides the ability to measure a broad range of antibody titers within diverse clinical populations. Due to its increased sensitivity and dynamic range, the LEXA was able to more effectively measure anti-Pn IgG in adults compared to ELISA. This suggests that the LEXA, may be able to determine the protective role of a specific antibody even in adults, who generally have been exposed to massive amounts of different antigens over a lifetime that cross-react with the antigen in question. Conclusion Flow Application’s modified use of the Luminex platform provides a comprehensive assay system that can be applied to virtually any application that requires analysis of anti- Pn antibody, basic research, clinical diagnostic testing, environmental testing, and agricultural testing. The Luminex bead technology, as adapted by Flow Application, is unique in its ability to provide multiplexed, high-throughput analysis coupled with real- time data analysis. The assay system offers excellent sensitivity, precision, speed, and economy for the measurement of Pn antibody. RESULTS Vaccination of pregnant women during their third trimester was safe and immunogenic. The LEXA was compared to the standard ELISA for quantitation of IgG antibodies to each of the 5 Pn serotypes using sera collected from mothers pre and post vaccination. Antibody concentrations for each of the tested sera were subjected to linear regression analysis with the results shown in Figure 3. The correlation coefficients (r-value) showed a range of 0.53 to 0.96 for mothers’ sera run against the 5 Pn serotypes. ELISA values never demonstrated 0 antibody levels due to background noise. The lower limit of detection for the LEXA has not been established at this time. This will be described in later work. As a result, technical limitations exist for the assay on the lower end. A quality WHO panel of 12 Goldblatt Pn sera was used to evaluate the LEXA for 5 Pn serotpes (Table 2). Correlation coefficient values were considered good for each of the serotypes tested and suggest the two assays (ELISA vs. LEXA) result in very similar IgG concentrations. Total IgG antibodies to pneumococcal serotypes 4, 6B, 9V, 14, 19F were successfully measured in mothers in both the standard ELISA and LEXA before and 4 weeks after vaccination with the 23-valent PS vaccine (Table 3). Although the vaccine response varied considerably among individuals to each of the 5 serotypes, vaccination with PnPs during pregnancy resulted in higher post-vaccination concentrations of pneumococcal IgG antibodies for all 5 vaccine serotypes in both assays, demonstrating the sensitivity of the assay (Table 3). Fold-increase responses among the LEXA post- vaccination values compared to pre-values were consistently higher than that observed for ELISA (Table 3). Correlation values are presented for the WHO reference sera and the clinical trial samples (Table 3). The 5 Pn serotypes, when tested with the standardized WHO sera set, yielded results that achieved 83% compliance the FDA?WHO criteria. Measurements for limits of detection, sensitivity, and robustness are being evaluated for LEXA. Linearity and specificity have been established through previous published work. Mean ug of IgG/ml SerotypePre-vaccinationPost-vaccinationFold Increase – Pre vs. Post ELISALEXAELISALEXAELISALEXA 4 6B 9V 14 19F Blood samples were obtained 4 weeks post-vaccination with 23 valent PnPs vaccine Contact information: David L. Klein Acknowledgements Special thanks to the Respiratory Disease Branch, CDC METHODS GestationDelivery/ Birth After Birth (mother and infant) Groups32 Wks36 Wks0 weeks6 weeks10 weeks14 weeks18 weeks 22 weeks 1MMM, B, NP B, BM, NP BM, NP 2MMM, B, NP B, BM, NP BM, NP 3MMM, B, NP B, BM, NP BM, NP BM, MP 4MMM, B, NP B, BM, NP BM, NP M – Maternal Blood Specimens B – Infant Blood Specimens BM – Breast Milk NP – Nasopharyngeal Cultures for S. pneumoniae Isolation and Serotyping Figure 1. Luminex assay Figure 2. Table 2 Table 3. Figure 3. Table 1. Vaccination and Specimen Collection Schedule by Study Group